Game-Changing Merger: TransCode Therapeutics Acquires Polynoma, Secures $25M for Pancreatic Cancer Breakthrough

In a strategic move poised to accelerate groundbreaking cancer therapies, TransCode Therapeutics, a leader in RNA therapeutics, has officially announced its acquisition of Polynoma, Inc. This significant all-stock transaction is coupled with a substantial $25 million investment from institutional investors, earmarked to propel the clinical development of TransCode's lead asset, TCX-801, for the treatment of pancreatic cancer.

The acquisition of Polynoma represents a powerful synergy, bringing together Polynoma's profound expertise in tumor-associated antigens and glycoproteins with TransCode's innovative RNA-targeting platform.

This integration is expected to not only expand TransCode's therapeutic pipeline but also enhance its capabilities in tackling some of the most challenging cancers.

TCX-801, TransCode's flagship therapeutic candidate, targets the critical RNA sequences involved in pancreatic cancer progression.

The infusion of $25 million is a direct testament to the confidence investors have in this promising asset and its potential to revolutionize treatment outcomes for patients suffering from this aggressive disease. Pancreatic cancer remains one of the most difficult cancers to treat, with a high mortality rate, making advancements in this area critically important.

As part of this strategic realignment, Dr.

Dirk Hosemann, a prominent figure with extensive experience in oncology and biotechnology, is set to join TransCode's Board of Directors. His leadership and insights are expected to provide invaluable guidance as the company navigates the complex landscape of clinical development and regulatory approvals.

The combined entity is now strategically positioned to accelerate the development of a broader range of RNA-based therapies, leveraging Polynoma's unique insights into tumor biology.

This expanded pipeline promises to address unmet medical needs across various cancer types, beyond just pancreatic cancer, offering hope for more effective and targeted treatments in the future.

TransCode Therapeutics is dedicated to advancing precision medicine through its cutting-edge RNA interference technology.

By silencing specific cancer-promoting genes, their therapies aim to offer a more precise and less toxic approach compared to traditional treatments. This acquisition and investment underscore their commitment to translating scientific innovation into tangible patient benefits, marking a pivotal moment in their journey to combat cancer.